Disappointments in the treatment of acute viral infections: What's the problem?

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 591-592

  Pillay, Deenan ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ORAL CONTRACEPTIVE AGENT; OSELTAMIVIR; PLECONARIL; SIALIDASE INHIBITOR; ZANAMIVIR;

BRONCHOSPASM; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EPIDEMIC; HEALTH CARE COST; HEPATITIS B; HEPATITIS C; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; NONHUMAN; SIDE EFFECT; VIRUS INFECTION;

EID: 0036919728     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00006     Document Type: Editorial

References (7)

1. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337:927-928.
2. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomised controlled trial. JAMA 2000; 283:1057-1059.
3. Hayden FG, Coats T, Kim K, et al. Oral pleconaril treatment of picomavirus-associated viral respiratory illness in adults: Efficacy and tolerability in phase II clinical trials. Antivir Ther 2002; 7:53-65.
4. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Antiviral Drugs Advisory Committee; 19 March 2002.
5. Guidance on the use of zanamivir (Relenza) in the treatment of influenza. Technology Appraisal Guidance No. 15. National Institute for Clinical Excellence; November 2000.
6. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neurambidase inhibitor oseltamivir prevent influenza. N Engl J Med 1999; 341:1336-1343.
7. Hayden FG, Gubareva LV, Monto AS. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000; 343:1282-1289.